首页> 外文期刊>World Journal of Gastroenterology >Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer.
【24h】

Clinicopathological significance of Bcl-2 and Bax protein expression in human pancreatic cancer.

机译:Bcl-2和Bax蛋白在人类胰腺癌中的表达及其临床病理意义。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To assess the clinicopathological significance of the expression of the apoptosis-inhibitory Bcl-2 protein (pBcl-2) and the apoptosis-promoting Bax protein (pBax) in human invasive ductal carcinomas (IDCs) of the pancreas. METHODS: Fifty-nine surgical specimens of IDCs of the pancreas were stained immunohistochemically to detect pBcl-2 and pBax expressions whose correlation to tumor classification, staging, and prognosis was analyzed by univariate and multivariate analyses. RESULTS: The expression of pBcl-2 and pBax was detected in 21 of 59 (35.6%) and in 29 of 59 (49.2%) patients with IDCs of the pancreas, respectively. Neither pBcl-2 nor pBax alone was correlated to TNM staging and differentiation degree of IDCs of the pancreas according to univariate analysis. By Mantel-Cox test, the median survival time after surgery for pBcl-2(+) and pBcl-2(-) groups were 14.3 and 7.3 mo, respectively (chi(2) = 9.357, P = 0.002) and that for pBax(+) and pBax(-) groups were 12.9 and 10.2 mo, respectively (chi(2) = 0.285, P>0.05). Contingency coefficient between pBcl-2 and pBax expression was 0.298, indicating that there was correlation between them (chi(2) = 5.74, P<0.05). The median survival time after surgery for pBcl-2(+)pBax(+) and pBcl-2(+)pBax(-) groups were 14.3 and 14.1 mo, respectively, and that for pBcl-2(-)pBax(+) and pBcl-2(-)pBax(-) groups were 5.9 and 9.9 mo, respectively. There was a significant difference between pBcl-2(+)pBax(+) and pBcl-2(-)pBax(+) (chi(2) = 5.06, P<0.05), such was the case for pBcl-2(+)pBax(+) and pBcl-2(-)pBax(-) (chi(2) = 7.18, P<0.01). Cox proportional hazards model for multivariate analysis was applied, indicating that pBcl-2, TNM staging, age and pBax were high risk factors of post-surgical survival time. CONCLUSION: Both pBcl-2 and pBax have high expression in IDCs of the pancreas, indicating that co-expression of pBcl-2 and pBax is a good indicator of favorable prognosis in IDCs of the pancreas.
机译:目的:评估凋亡抑制性Bcl-2蛋白(pBcl-2)和促凋亡Bax蛋白(pBax)在胰腺癌中的临床病理学意义。方法:对59例胰腺IDC手术标本进行免疫组织化学染色,通过单因素和多因素分析分析pBcl-2和pBax表达与肿瘤分类,分期和预后的关系。结果:分别在59例胰腺IDC患者中检测到pBcl-2和pBax的表达,分别为59例中的21例(35.6%)和59例中的29例(49.2%)。单因素分析表明,pBcl-2和pBax均与胰腺癌的IDM的TNM分期和分化程度无关。通过Mantel-Cox检验,pBcl-2(+)和pBcl-2(-)组的中位生存时间分别为14.3和7.3 mo(chi(2)= 9.357,P = 0.002)和pBax (+)和pBax(-)组分别为12.9和10.2 mo(chi(2)= 0.285,P> 0.05)。 pBcl-2和pBax表达之间的权变系数为0.298,表明它们之间存在相关性(chi(2)= 5.74,P <0.05)。 pBcl-2(+)pBax(+)和pBcl-2(+)pBax(-)组的手术后中位生存时间分别为14.3和14.1 mo,pBcl-2(-)pBax(+)组的中位生存时间分别为14.3和14.1 mo。和pBcl-2(-)pBax(-)组分别为5.9和9.9 mo。 pBcl-2(+)pBax(+)和pBcl-2(-)pBax(+)之间存在显着差异(chi(2)= 5.06,P <0.05),pBcl-2(+)就是这种情况pBax(+)和pBcl-2(-)pBax(-)(chi(2)= 7.18,P <0.01)。应用Cox比例风险模型进行多变量分析,表明pBcl-2,TNM分期,年龄和pBax是术后生存时间的高风险因素。结论:pBcl-2和pBax均在胰腺的IDC中高表达,表明pBcl-2和pBax的共表达是胰腺IDCs预后良好的良好指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号